135 related articles for article (PubMed ID: 28024400)
1. Cheminformatics Modeling of Adverse Drug Responses by Clinically Relevant Mutants of Human Androgen Receptor.
Paul N; Carabet LA; Lallous N; Yamazaki T; Gleave ME; Rennie PS; Cherkasov A
J Chem Inf Model; 2016 Dec; 56(12):2507-2516. PubMed ID: 28024400
[TBL] [Abstract][Full Text] [Related]
2. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
3. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
[TBL] [Abstract][Full Text] [Related]
4. Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.
Lallous N; Leblanc E; Munuganti RS; Hassona MD; Nakouzi NA; Awrey S; Morin H; Roshan-Moniri M; Singh K; Lawn S; Yamazaki T; Adomat HH; Andre C; Daugaard M; Young RN; Guns ES; Rennie PS; Cherkasov A
Mol Cancer Ther; 2016 Dec; 15(12):2936-2945. PubMed ID: 27765852
[TBL] [Abstract][Full Text] [Related]
5. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).
Korpal M; Korn JM; Gao X; Rakiec DP; Ruddy DA; Doshi S; Yuan J; Kovats SG; Kim S; Cooke VG; Monahan JE; Stegmeier F; Roberts TM; Sellers WR; Zhou W; Zhu P
Cancer Discov; 2013 Sep; 3(9):1030-43. PubMed ID: 23842682
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a new class of androgen receptor antagonists with potential therapeutic application in advanced prostate cancer.
Li H; Hassona MD; Lack NA; Axerio-Cilies P; Leblanc E; Tavassoli P; Kanaan N; Frewin K; Singh K; Adomat H; Böhm KJ; Prinz H; Guns ET; Rennie PS; Cherkasov A
Mol Cancer Ther; 2013 Nov; 12(11):2425-35. PubMed ID: 23939374
[TBL] [Abstract][Full Text] [Related]
7. Structural and molecular insights into the mechanism of resistance to enzalutamide by the clinical mutants in androgen receptor (AR) in castration-resistant prostate cancer (CRPC) patients.
Khan A; Mao Y; Tahreem S; Wei DQ; Wang Y
Int J Biol Macromol; 2022 Oct; 218():856-865. PubMed ID: 35905763
[TBL] [Abstract][Full Text] [Related]
8. Resistance emerges to second-generation antiandrogens in prostate cancer.
Nelson WG; Yegnasubramanian S
Cancer Discov; 2013 Sep; 3(9):971-4. PubMed ID: 24019330
[TBL] [Abstract][Full Text] [Related]
9. [Enzalutamide-a novel androgen receptor inhibitor that provides treatment options for patients with castration-resistant prostate cancer].
Maeda H; Saito A
Gan To Kagaku Ryoho; 2014 Jul; 41(7):805-10. PubMed ID: 25131864
[TBL] [Abstract][Full Text] [Related]
10.
Özgür E; Celik AI; Darendeliler E; Gezer U
Anticancer Res; 2017 Jul; 37(7):3631-3637. PubMed ID: 28668854
[TBL] [Abstract][Full Text] [Related]
11. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
Patki M; Huang Y; Ratnam M
Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Novel Androgen Receptor Ligands by Structure-based Virtual Screening and Bioassays.
Zhou W; Duan M; Fu W; Pang J; Tang Q; Sun H; Xu L; Chang S; Li D; Hou T
Genomics Proteomics Bioinformatics; 2018 Dec; 16(6):416-427. PubMed ID: 30639122
[TBL] [Abstract][Full Text] [Related]
13. Non-Steroidal Androgen Receptor Antagonists and Prostate Cancer: A Survey on Chemical Structures Binding this Fast-Mutating Target.
Ferroni C; Varchi G
Curr Med Chem; 2019; 26(33):6053-6073. PubMed ID: 30209993
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer.
Bai Y; Zhang Z; Cheng L; Wang R; Chen X; Kong Y; Feng F; Ahmad N; Li L; Liu X
J Biol Chem; 2019 Jun; 294(25):9911-9923. PubMed ID: 31085587
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
16. Down-Regulation of the Androgen Receptor by G-Quadruplex Ligands Sensitizes Castration-Resistant Prostate Cancer Cells to Enzalutamide.
Tassinari M; Cimino-Reale G; Nadai M; Doria F; Butovskaya E; Recagni M; Freccero M; Zaffaroni N; Richter SN; Folini M
J Med Chem; 2018 Oct; 61(19):8625-8638. PubMed ID: 30188709
[TBL] [Abstract][Full Text] [Related]
17. ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.
Wang R; Lin W; Lin C; Li L; Sun Y; Chang C
Cancer Lett; 2016 Aug; 379(1):154-60. PubMed ID: 27233475
[TBL] [Abstract][Full Text] [Related]
18. Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.
Kregel S; Chen JL; Tom W; Krishnan V; Kach J; Brechka H; Fessenden TB; Isikbay M; Paner GP; Szmulewitz RZ; Vander Griend DJ
Oncotarget; 2016 May; 7(18):26259-74. PubMed ID: 27036029
[TBL] [Abstract][Full Text] [Related]
19. Cheminformatics Driven Development of Novel Therapies for Drug Resistant Prostate Cancer.
Ban F; Dalal K; LeBlanc E; Morin H; Rennie PS; Cherkasov A
Mol Inform; 2018 Sep; 37(9-10):e1800043. PubMed ID: 29733509
[TBL] [Abstract][Full Text] [Related]
20. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
